Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Palisade Bio presented five posters at ACG 2026 supporting the Phase 2 rationale for PALI-2108, its gut-activated PDE4 inhibitor prodrug, in ulcerative colitis and Crohn's disease. Phase 1a/1b data showed early activity — all five UC patients achieved clinical response with a 62.8% mean reduction in modified Mayo score, and fibrostenotic Crohn's patients showed a 47.5% mean SES-CD reduction after 14 days — with no serious adverse events. Two posters received ACG Presidential Poster Awards, a distinction given to roughly 5% of accepted abstracts. The Phase 2 ASCENTRA-UC study will test 15 mg and 30 mg once-daily doses versus placebo in approximately 204 patients.
Key figures
- Drug Name
- PALI-2108
- Phase Of Trial
- Phase 2
- Ses cd reduction
- 47.5%
- Mayo score reduction
- 62.8%
- Phase2 uc trial size
- 204
- Transcriptomic samples
- approximately 3,000
- Tissue vs plasma exposure
- ~sevenfold higher
- Presidential poster awards
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.